? Center for In Vivo Imaging and Therapeutics The Center for In Vivo Imaging and Therapeutics (CIVIT) is an SJCCC-managed Shared Resource with the overarching goal of providing cutting-edge imaging and image-guided therapy technologies to advance preclinical cancer modeling research. As part of the SJCCC Strategic Plan, the HMP, DBSTP, NBTP, and CBP prioritized enhanced animal modeling as a central requirement for their preclinical research endeavors, with CIVIT at the center of these plans. CIVIT plays a major role in advancing SJCCC preclinical research by offering leading surgical and imaging expertise, allowing Program members to readily model and survey genetic and orthotopic-implant models of brain tumors, solid tumors, and leukemias. CIVIT partners with SJCCC members to provide consultative and technical expertise in modeling and conducting experiments for their preclinical research. The core also offers seminars to educate users about new preclinical imaging applications and technologies. CIVIT is directed by Dr. Walter Akers, an NCI R50-funded veterinarian and biomedical engineer with more than 11 years of experience in cancer imaging and therapy research. He is supported by 1 staff scientist and 6 highly skilled research technologists to provide imaging, surgery, and therapeutic services, and partner with SJCCC groups in planning and performing experiments to ensure animal studies are conducted at the highest standard. The impact of the CIVIT on the cancer research of the Programs is evidenced by the high level of collaborative publications and key scientific contributions in high-impact journals such as Blood (n=5), Nature Genetics (n=3), and Cancer Cell (n=6). During the current funding period, 66 publications from January 2013?December 2017 used the CIVIT, representing 28 (42%) interprogrammatic and 33 (50%) intraprogrammatic collaborations. These included publications from 4 of the 5 Programs: DBSTP (n=16), HMP (n=25), CBP (n=34), and NBTP (n=25). During the index year (FY2017), 94% of all investigators using the CIVIT were SJCCC members (49/52). Goals for the next period include upgrading high-frequency ultrasounds (Vevo 3100, Visualsonics) to provide state-of-the-art capabilities for image-guided injections and tumor volume measurement; obtaining a fluorescence-capable surgical microscope to optimize brainstem O-PDX implantation and image-guided resections of O-PDX tumors in mice; and upgrading the IGRT system with BLI capability (Muriglo, Xstrahl) to enable tumor-selective radiation for preclinical trials. These advanced technologies will ensure continued high-level support of the preclinical research of the SJCCC Programs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Hoehn, Mary Ellen; Calderwood, Julie; Gannon, Edwin et al. (2018) Ocular complications in a young pediatric population following bone marrow transplantation. J AAPOS 22:102-106.e1
Devine, Katie A; Mertens, Ann C; Whitton, John A et al. (2018) Factors associated with physical activity among adolescent and young adult survivors of early childhood cancer: A report from the childhood cancer survivor study (CCSS). Psychooncology 27:613-619
Matreyek, Kenneth A; Starita, Lea M; Stephany, Jason J et al. (2018) Multiplex assessment of protein variant abundance by massively parallel sequencing. Nat Genet 50:874-882
Hazlitt, Robert A; Min, Jaeki; Zuo, Jian (2018) Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss. J Med Chem 61:5512-5524
Khan, Raja B; Merchant, Thomas E; Sadighi, Zsila S et al. (2018) Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. J Neurooncol 136:379-384
Zimmerman, Mark W; Liu, Yu; He, Shuning et al. (2018) MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discov 8:320-335
Hammill, Jared T; Bhasin, Deepak; Scott, Daniel C et al. (2018) Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation. J Med Chem 61:2694-2706
Li, Yanfeng; Bakke, Jesse; Finkelstein, David et al. (2018) HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. Oncogenesis 7:9
Browne, Emily K; Zhou, Yinmei; Chemaitilly, Wassim et al. (2018) Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia. Cancer 124:4248-4259
Ehrhardt, Matthew J; Mulrooney, Daniel A; Li, Chenghong et al. (2018) Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma. Cancer 124:417-425

Showing the most recent 10 out of 6764 publications